Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine

For lenvatinib (Lenvima, Eisai)

Adults with 'progressive, locally advanced or metastatic differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma, refractory to radioactive iodine'.

Sorafenib (Nexavar, Bayer)

Adults with 'progressive, locally advanced or metastatic differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma, refractory to radioactive iodine'.

For lenvatinib 24 mg (2×10 mg capsules and 1×4 mg capsule) once daily.

Treatment should continue as long as clinical benefit is observed or until unacceptable toxicity occurs.

For sorafenib 400 mg (2×200 mg tablets) twice daily (equivalent to a total daily dose of 800 mg).

Treatment should continue as long as clinical benefit is observed or until unacceptable toxicity occurs.

For lenvatinib £1,437 per 30×10 mg pack and per 30×4 mg pack (excluding VAT; British national formulary online [accessed July 2017]).

The company has a commercial arrangement. This makes lenvatinib available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.

For sorafenib £3,576.56 per 112×200 mg pack (excluding VAT; British national formulary online [accessed July 2017]).

The company has a commercial arrangement. This makes sorafenib available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.